cms or cms promoter activators alone or in combination with pde5 inhibitors for the treatment of cystic fibrosis

摘要

the present invention relates to a soluble guanylate cyclase (sgc), and phosphodiesterases (pde) and the pharmacology of agents and inhibitors of sgc sgc activators of pde.more particularly, the invention relates to the use of pacemakers of cms and cms activators in combination with pde5 inhibitors for the preparation of drugs for the treatment of cystic fibrosis (cf).